227: Treat PsA from the Start: Consider Otezla for Patients Who Need More Than an NSAID

Saturday, November 12, 2022

6:30 PM – 8:30 PM Eastern Time

Location: Marriott, Grand Ballroom H

All of the relevant financial relationships listed for faculty have been mitigated.

Industry Presenter(s)

Philip Mease, MD

Rheumatologist, Director of Rheumatology Research, Clinical Professor Director of Rheumatology Research Swedish Medical Center/Providence-St Joseph Health
Swedish Medical Center/Providence St. Joseph Health
Seattle, WA, United States

Disclosure information not submitted.

Join our educational discussion on the heterogeneous nature of PsA which emphasizes the need for early diagnosis and treatment of disease.

Developed and offered by Amgen

Learning Objectives:

Discuss the burden of disease burden of psoriatic arthritis in patients with disease in difficult-to-treat areas.
Review Otezla's efficacy and breadth of data in plaque psoriasis for patients, when topicals are not enough.
Explain the correlation in psoriasis and psoriatic arthritis and present efficacy and safety data in PsA.